A meta-analysis study at the Umea University, Sweden shows no reduction in the risk of cardiovascular disease and death (mortality) with the treatment to lower the blood pressure in the healthy people with the systolic blood pressure below 140 mm Hg.
The Systolic Blood Pressure Intervention Trial (SPRINT), a previous study in 2015 has found a reduction in the mortality and cardiovascular disease with a systolic blood pressure less than 120 mm Hg. But the current study shows an opposite to the result of the SPRINT study and support the current guidelines.
Researchers have conducted a meta-analysis on 74 randomized clinical trials conducted on 306,273 patients. The average age of the patients was 63.6 years. About 39.9 percent of them were women. The analytical study has found the following.
Researchers say that the treatments to lower the blood pressure below 130 mm Hg is beneficial to the people with a coronary heart disease. The treatment effect was neutral in the primary prevention trials.
Lead author of the study was Dr. Mattias Brannstrom, MD, Ph.D., a researcher, the Department of Public Health and Clinical Medicine, Umea University, Sweden. The study was published on October 1, 2017, in the JAMA Internal Medicine. Title of the article was "Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis."
The drug Trodusquemine was effective in the following.
A current study at the University of Aberdeen, Scotland, shows a reduction in arterial fat and a possible reversal of atherosclerosis (a risk factor for heart and cardiovascular diseases. CVD) with the drug Trodusquemine.
A preclinical study on the mice models shows that the drug Trodusquemine has the ability to dissolve the plaque and the fat in the arteries. In some cases, just one dose is sufficient for the reversal of atherosclerosis. The study shows a decrease in the measured plaque formation, a complete reversal of atherosclerosis effects and the prevention of the risk associated with occlusion and thrombosis events.
The dosage of the drug Trodusquemine, either once a week for five weeks or just once at the end of the study has resulted in a marked reduction in the atherosclerotic plaque and a lower level of cholesterol and triglycerides.
Authors of the study were Professor Mirela Delibegovic and Dr. Dawn Thompson from the University of Aberdeen's Institute of Medical Sciences, Aberdeen, Scotland. The study was published on September 29, 2017, in Clinical Science. Title of the article was "Pharmacological inhibition of protein tyrosine phosphatase 1B protects against atherosclerotic plaque formation in the LDLR-/- mouse model of atherosclerosis."
Occlusion: A clot formed in the artery and blocking the flow of blood is known as vascular occlusion. The blockage may be partial or full. The occlusion can lead to a heart attack. The occlusion can be diagnosed with an ultrasound technique known as the Doppler sonography.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.